Literature DB >> 1302181

Evolution of secondary metabolite production: potential roles for antibiotics as prebiotic effectors of catalytic RNA reactions.

J Davies1, U von Ahsen, H Wank, R Schroeder.   

Abstract

It has been proposed that organic molecules related to known secondary metabolites have existed since the beginning of biochemical evolution and were present in primordial soups. Under primitive earth conditions certain of these molecules may have played roles as effectors in prebiotic reactions, especially those involving catalytic RNA (ribozymes). We demonstrate that a number of antibiotic-related secondary metabolites bind to group I introns and either inhibit splicing reactions or promote the formation of intron oligomers. This is consistent with the functional co-evolution of catalytic RNA and secondary metabolites as antibiotic inhibitors of translation, and supports the notion of an evolutionary relationship between group I introns and ribosomal RNA.

Mesh:

Substances:

Year:  1992        PMID: 1302181     DOI: 10.1002/9780470514344.ch3

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  4 in total

Review 1.  Antibiotics and evolution: food for thought.

Authors:  C R Strachan; J Davies
Journal:  J Ind Microbiol Biotechnol       Date:  2015-11-02       Impact factor: 3.346

2.  Combined, functional genomic-biochemical approach to intermediary metabolism: interaction of acivicin, a glutamine amidotransferase inhibitor, with Escherichia coli K-12.

Authors:  D R Smulski; L L Huang; M P McCluskey; M J Reeve; A C Vollmer; T K Van Dyk; R A LaRossa
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

3.  Enhancement of Neurospora VS ribozyme cleavage by tuberactinomycin antibiotics.

Authors:  J E Olive; D M De Abreu; T Rastogi; A A Andersen; A K Mittermaier; T L Beattie; R A Collins
Journal:  EMBO J       Date:  1995-07-03       Impact factor: 11.598

4.  Short RNA guides cleavage by eukaryotic RNase III.

Authors:  Bruno Lamontagne; Sherif Abou Elela
Journal:  PLoS One       Date:  2007-05-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.